BEIZRAY

Growth

docetaxel

NDAINTRAVENOUSSOLUTION

Approved

Oct 2024

Lifecycle

Growth

Competitive Pressure

0/100

Clinical Trials

Mechanism of Action

functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly. This leads to the production of microtubule bundles without normal function and to the stabilization of microtubules, which results in the…

Pharmacologic Class:

Microtubule Inhibitor

Indications (8)

metastatic breast cancer after failure of prior chemotherapy metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy locally advanced metastatic non-small cell lung cancer including adenocarcinoma of the gastroesophageal junction Breast Cancer Lung Cancer Prostate Cancer

Clinical Trials (5)

NCT07361484Phase 3Not Yet Recruiting

Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)

Started Jun 2026

NCT07313891Phase 3Not Yet Recruiting

A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

Started May 2026

NCT07416994Phase 3Not Yet Recruiting

Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer

Started Mar 2026

NCT07354984Phase 2Not Yet Recruiting

A Single-Arm Phase II Clinical Study of Docetaxel Combined With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Started Jan 2026

NCT07225946Phase 3Recruiting

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Started Dec 2025

800 enrolled

Prostatic Neoplasms, Castration-Resistant